Company intelligence / Profile preview

OTY

Cambridge, Massachusetts, United States

Ownership: Private
Development stage: Other

Overview

Oty is a stealth-mode biotechnology company focused on developing a new class of medicines to treat immune-mediated diseases. The company leverages advanced synthetic biology and immune system reprogramming technologies to create therapies that can precisely modulate immune responses. Founded by pioneers in the CRISPR and genome engineering fields, Oty aims to address the underlying causes of autoimmunity and chronic inflammation. The company is currently in the pre-clinical stage, building a pipeline of programs designed to restore immune balance in patients with limited treatment options.

Therapeutic areas: Immunology
Modalities: Cell therapySynthetic biology
Industry: Biotech

Beyond the preview

Go deeper on OTY.

Explore clinical development, deal activity, and the competitive landscape with Gosset’s full data platform.

Clinical trials

Follow clinical development from trial design and recruitment through results.

Trial phase
Status
Readouts

Licensing & deals

Explore licensing agreements, acquisitions, and the assets behind each deal.

Partners
Deal terms
Milestones

Funding history

Trace financing activity and the investors behind a company’s development.

Funding rounds
Investors
Capital raised

Competitive landscape

Compare peer pipelines by target, modality, and therapeutic area.

Peer companies
Targets
Pipeline overlap

Technologies & patents

Explore technology platforms and the patent landscape around relevant assets.

Platforms
Patents
Assignees

Research & analysis

Connect company news and source material to the questions you’re investigating.

Company news
Sources
Analysis

Bring the full picture into focus.

See how Gosset can support your research on OTY.

Explore the full profile